Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) administration in mice, an experimental model of parkinson's disease

Neurotoxicity Research

Volumn 25, Issue 1, 2014, Pages 24-32

  Tristão, Fabrine S M ^a   Amar, Majid ^a   Latrous, Ines ^a   Del Bel, Elaine A ^b   Prediger, Rui D ^c   Raisman Vozari, Rita ^a,d,e,f  

^a INSERM   (France)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^d SORBONNE UNIVERSITÉ   (France)

^e CNRS   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Intranasal; MPTP; Neurodegeneration; Neuroinflammation; Parkinson's disease; Subacute

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; TYROSINE 3 MONOOXYGENASE;

ACUTE DRUG ADMINISTRATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN REGION; C57BL 6 MOUSE; CONTROLLED STUDY; CORPUS STRIATUM; GLIOSIS; HYPERTROPHY; INTOXICATION; MALE; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NOSE CAVITY; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; ANIMAL; C57BL MOUSE; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; EVALUATION STUDY; INFLAMMATION; INTRANASAL DRUG ADMINISTRATION; PATHOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADMINISTRATION, INTRANASAL; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ENVIRONMENTAL EXPOSURE; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEURODEGENERATIVE DISEASES; SUBSTANTIA NIGRA;

EID: 84886095184     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-013-9401-8     Document Type: Article

References (60)

1. Aguiar AS Jr., Tristao FSM, Amar M, Chevarin C, Lanfumey L, Mongeau R, Corti O, Prediger RD, Raisman-Vozari R (2013) Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurotox Res. doi: 10.1007/s12640-013-9389-0
2. Anandhan A, Janakiraman U, Manivasagam T (2012) Theaflavin ameliorates behavioral deficits, biochemical indices and monoamine transporters expression against subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease. Neuroscience 218:257-267
3. Aoki E, Yano R, Yokoyama H, Kato H, Araki T (2009) Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp Mol Pathol 86:57-64
4. Aubin N, Curet O, Deffois A, Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71:1635-1642 (Pubitemid 28443036)
5. Ballard PA, Tetrud JW, Langston JW (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35:949-956 (Pubitemid 15026264)
6. Bezard E, Yue Z, Kirik D, Spillantini MG (2012) Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord. doi: 10.1002/mds.25108
7. Block ML, Hong JS (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76:77-98 (Pubitemid 41242883)
8. Bove J, Perier C (2012) Neurotoxin-based models of Parkinson's disease. Neuroscience 211:51-76
9. Bove J, Prou D, Perier C, Przedborski S (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2:484-494 (Pubitemid 41444882)
10. Castro AA, Ghisoni K, Latini A, Quevedo J, Tasca CI, Prediger RD (2012) Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. Behav Brain Res 229:208-215
11. Chiba K, Kubota E, Miyakawa T, Kato Y, Ishizaki T (1988) Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Pharmacol Exp Ther 246:1108-1115
12. Chiueh CC, Markey SP, Burns RS, Johannessen JN, Pert A, Kopin IJ (1984) Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur J Pharmacol 100:189-194 (Pubitemid 14138269)
13. Choi DK, Pennathur S, Perier C, Tieu K, Teismann P, Wu DC, Jackson-Lewis V, Vila M, Vonsattel JP, Heinecke JW, Przedborski S (2005) Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci 25:6594-6600 (Pubitemid 40995291)
14. Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH, Jin BK (2010) The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Rep 43:225-232
15. Ciesielska A, Joniec I, Kurkowska-Jastrzebska I, Cudna A, Przybylkowski A, Czlonkowska A, Czlonkowski A (2009) The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease. Inflamm Res 58:747-753
16. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65:1-105 (Pubitemid 32479155)
17. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909 (Pubitemid 37130207)
18. Dluzen DE, Kefalas G (1996) The effects of intranasal infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice. Brain Res 741:215-219 (Pubitemid 26426318)
19. Doty RL (2008) The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol 63:7-15 (Pubitemid 351240546)
20. Fletcher L, Kohli S, Sprague SM, Scranton RA, Lipton SA, Parra A, Jimenez DF, Digicaylioglu M (2009) Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke: laboratory investigation. J Neurosurg 111:164-170
21. Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259-272 (Pubitemid 26085575)
22. Fuller RW, Hemrick-Luecke SK (1990) Tissue concentrations of MPTP and MPP+ after administration of lethal and sublethal doses of MPTP to mice. Toxicol Lett 54:253-262
23. Gibrat C, Saint-Pierre M, Bousquet M, Levesque D, Rouillard C, Cicchetti F (2009) Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J Neurochem 109:1469-1482
24. Gordon GR, Choi HB, Rungta RL, Ellis-Davies GC, MacVicar BA (2008) Brain metabolism dictates the polarity of astrocyte control over arterioles. Nature 456:745-749
25. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8:382-397
26. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348
27. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269
28. Kalaria RN, Mitchell MJ, Harik SI (1987) Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. Proc Natl Acad Sci USA 84:3521-3525 (Pubitemid 17085436)
29. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, Pownall S, Wakeham A, You-Ten AJ, Kalia SK, Horne P, Westaway D, Lozano AM, Anisman H, Park DS, Mak TW (2005) Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 102:5215-5220
30. Lazzarini M, Martin S, Mitkovski M, Vozari RR, Stühmer W, Bel ED (2013) Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model. Glia. doi: 10.1002/glia.22496
31. Lewy FH (1912) Paralysis agitans. In: Lewandowsky M (ed) Pathologische Anatomie. Handbuch der Neurologie. Springer-Verlag, Berlin, pp 920-933
32. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5:1403-1409
33. Mayeux R (2003) Epidemiology of neurodegeneration. Annu Rev Neurosci 26:81-104 (Pubitemid 37064929)
34. McGeer PL, Itagaki S, Akiyama H, McGeer EG (1988) Rate of cell death in Parkinsonism indicates active neuropathological process. Ann Neurol 24:574-576
35. Meredith GE, Totterdell S, Potashkin JA, Surmeier DJ (2008) Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 14(Suppl 2):S112-S115
36. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165:208-210 (Pubitemid 24043277)
37. Moreira EL, Rial D, Aguiar AS Jr, Figueiredo CP, Siqueira JM, DalBo S, Horst H, de Oliveira J, Mancini G, dos Santos TS, Villarinho JG, Pinheiro FV, Marino-Neto J, Ferreira J, De Bem AF, Latini A, Pizzolatti MG, Ribeiro-do-Valle RM, Prediger RD (2010) Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine rat model of Parkinson's disease. J Neural Transm 117:1337-1351
38. Mulligan SJ, MacVicar BA (2004) Calcium transients in astrocyte endfeet cause cerebrovascular constrictions. Nature 431:195-199 (Pubitemid 39243473)
39. Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm 60:277-290 (Pubitemid 32037200)
40. Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS (2001) Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106:589-601 (Pubitemid 32925247)
41. Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN (2006) The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 202:391-403 (Pubitemid 44692682)
42. Prediger RD, Aguiar AS Jr, Rojas-Mayorquin AE, Figueiredo CP, Matheus FC, Ginestet L, Chevarin C, Bel ED, Mongeau R, Hamon M, Lanfumey L, Raisman-Vozari R (2010) Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. Neurotox Res 17:114-129
43. Prediger RD, Rojas-Mayorquin AE, Aguiar AS Jr, Chevarin C, Mongeau R, Hamon M, Lanfumey L, Del Bel E, Muramatsu H, Courty J, Raisman-Vozari R (2011) Mice with genetic deletion of the heparin-binding growth factor midkine exhibit early preclinical features of Parkinson's disease. J Neural Transm 118:1215-1225
44. Prediger RD, Aguiar AS Jr, Matheus FC, Walz R, Antoury L, Raisman-Vozari R, Doty RL (2012) Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease. Neurotox Res 21:90-116
45. Przedborski S, Vila M (2003) The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 991:189-198 (Pubitemid 36793814)
46. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akram M (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76:1265-1274 (Pubitemid 32198231)
47. Rojo AI, Montero C, Salazar M, Close RM, Fernandez-Ruiz J, Sanchez-Gonzalez MA, de Sagarra MR, Jackson-Lewis V, Cavada C, Cuadrado A (2006) Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. Eur J Neurosci 24:1874-1884 (Pubitemid 44583472)
48. Savitt JM, Dawson VL, Dawson TM (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116:1744-1754 (Pubitemid 44033293)
49. Sedelis M, Hofele K, Auburger GW, Morgan S, Huston JP, Schwarting RK (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30:171-182
50. Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134:57-66 (Pubitemid 40409495)
51. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251:205-208 (Pubitemid 28381082)
52. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP (2002) Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 16:1474-1476
53. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94:9938-9943 (Pubitemid 27408169)
54. Talegaonkar S, Mishra PR (2004) Intranasal delivery: an approach to bypass the blood brain barrier. Indian J Pharmacol 36:140-147 (Pubitemid 38787065)
55. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510-518
56. Tatton NA, Kish SJ (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037-1048 (Pubitemid 27128779)
57. Tower DB, Young OM (1973) The activities of butyrylcholinesterase and carbonic anhydrase, the rate of anaerobic glycolysis, and the question of a constant density of glial cells in cerebral cortices of various mammalian species from mouse to whale. J Neurochem 20:269-278
58. Vanzani MC, Iacono RF, Caccuri RL, Troncoso AR, Berria MI (2006) Regional differences in astrocyte activation in HIV-associated dementia. Medicina (B Aires) 66:108-112 (Pubitemid 43732835)
59. Wang WF, Wu SL, Liou YM, Wang AL, Pawlak CR, Ho YJ (2009) MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats. Behav Neurosci 123:1261-1270
60. Wang AL, Liou YM, Pawlak CR, Ho YJ (2010) Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats. Behav Brain Res 208:38-46